The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA
- PMID: 21479990
- PMCID: PMC3329939
- DOI: 10.1007/s00520-011-1141-9
The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. This analysis was performed to describe the relationship between numbness, tingling, and shooting/burning pain in patients with CIPN, as reported using the EORTC QLQ-CIPN20 (CIPN20).
Methods: Baseline CIPN20 data were provided for all patients on a prospective trial designed to treat patients with bothersome CIPN. Baseline frequencies for the items on the CIPN20 are primarily described by descriptive statistics and histograms, with correlational analyses between individual items.
Results: A majority of the 199 patients accrued to this study reported "quite a bit" to "very much" numbness (57%) or tingling (63%) in the hands compared to "a little" or "not at all" (numbness (43%), tingling (38%)). Fewer patients reported "quite a bit" to "very much" shooting/burning pain in the hands (18%). Numbness and tingling in the hands were highly correlated (r = 0.69), while neither were highly correlated with shooting/burning pain. Similar results were observed in the feet. More severe ratings for tingling and shooting/burning pain were ascribed to the lower extremities, as opposed to the upper extremities.
Conclusions: In patients with CIPN, severe sensory neuropathy symptoms (numbness, tingling) commonly exist without severe neuropathic pain symptoms (shooting/burning pain), while the reverse is not common. Symptoms in the feet should be evaluated distinctly from those in the hands as the experience of symptoms is not identical, for individual patients, in upper versus lower extremities.
Conflict of interest statement
Figures
Similar articles
-
Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.Eur J Cancer. 2016 Dec;69:28-38. doi: 10.1016/j.ejca.2016.09.020. Epub 2016 Nov 1. Eur J Cancer. 2016. PMID: 27814471
-
Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.Support Care Cancer. 2020 Dec;28(12):5933-5941. doi: 10.1007/s00520-020-05438-5. Epub 2020 Apr 12. Support Care Cancer. 2020. PMID: 32281032 Free PMC article.
-
Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Randomized Clinical Trial.J Pain. 2024 May;25(5):104431. doi: 10.1016/j.jpain.2023.11.014. Epub 2023 Nov 21. J Pain. 2024. PMID: 37993030 Free PMC article. Clinical Trial.
-
A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.Cancer. 2012 Apr 15;118(8 Suppl):2250-60. doi: 10.1002/cncr.27463. Cancer. 2012. PMID: 22488699 Review.
-
Chemotherapy-induced peripheral neuropathy - epidemiology and pathogenesis.Ginekol Pol. 2016;87(4):293-9. doi: 10.17772/gp/61750. Ginekol Pol. 2016. PMID: 27321102 Review.
Cited by
-
Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale.J Pain. 2015 Oct;16(10):1032-43. doi: 10.1016/j.jpain.2015.07.002. Epub 2015 Jul 22. J Pain. 2015. PMID: 26210041 Free PMC article.
-
Long-term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy.Cancer Med. 2020 Jul;9(14):5114-5123. doi: 10.1002/cam4.3129. Epub 2020 May 29. Cancer Med. 2020. PMID: 32469145 Free PMC article.
-
Management options for established chemotherapy-induced peripheral neuropathy.Support Care Cancer. 2014 Aug;22(8):2281-95. doi: 10.1007/s00520-014-2289-x. Epub 2014 May 31. Support Care Cancer. 2014. PMID: 24879391 Review.
-
Therapeutic Efficacy of Traditional Chinese Medicine Syndrome-Based Formulae to Neuropathic Pain Caused by Chemotherapy.Integr Cancer Ther. 2022 Jan-Dec;21:15347354221121095. doi: 10.1177/15347354221121095. Integr Cancer Ther. 2022. PMID: 36154520 Free PMC article.
-
The Relationship Between Evaluation Methods for Chemotherapy-Induced Peripheral Neuropathy.Sci Rep. 2019 Dec 30;9(1):20361. doi: 10.1038/s41598-019-56969-9. Sci Rep. 2019. PMID: 31889149 Free PMC article.
References
-
- Cavaletti G, et al. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995;75(5):1141–1150. - PubMed
-
- Cavaletti G, et al. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol. 1998;9(4):443–447. - PubMed
-
- Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer. 2004;12(9):619–625. - PubMed
-
- Pace A, et al. Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci. 1997;18 (2):73–79. - PubMed
-
- Rowinsky EK, et al. Neurotoxicity of taxol. J Natl Cancer Inst Monogr. 1993;15:107–115. - PubMed
Publication types
MeSH terms
Grants and funding
- U10 CA035267/CA/NCI NIH HHS/United States
- CA-37404/CA/NCI NIH HHS/United States
- K05 CA124477/CA/NCI NIH HHS/United States
- CA-35195/CA/NCI NIH HHS/United States
- U10 CA037404/CA/NCI NIH HHS/United States
- U10 CA035448/CA/NCI NIH HHS/United States
- CA-25224/CA/NCI NIH HHS/United States
- CA-124477/CA/NCI NIH HHS/United States
- CA-35113/CA/NCI NIH HHS/United States
- U10 CA035113/CA/NCI NIH HHS/United States
- U10 CA045377/CA/NCI NIH HHS/United States
- U10 CA035431/CA/NCI NIH HHS/United States
- CA-37417/CA/NCI NIH HHS/United States
- CA-35448/CA/NCI NIH HHS/United States
- U10 CA035103/CA/NCI NIH HHS/United States
- U10 CA037417/CA/NCI NIH HHS/United States
- N01 CA035431/CA/NCI NIH HHS/United States
- U10 CA063848/CA/NCI NIH HHS/United States
- U10 CA035195/CA/NCI NIH HHS/United States
- CA-35103/CA/NCI NIH HHS/United States
- CA-63848/CA/NCI NIH HHS/United States
- U10 CA035415/CA/NCI NIH HHS/United States
- U10 CA063849/CA/NCI NIH HHS/United States
- U10 CA067575/CA/NCI NIH HHS/United States
- CA-45377/CA/NCI NIH HHS/United States
- CA-35415/CA/NCI NIH HHS/United States
- N01 CA067575/CA/NCI NIH HHS/United States
- U10 CA025224/CA/NCI NIH HHS/United States
- CA-35267/CA/NCI NIH HHS/United States
- CA-63849/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical